|
|
|
| Expression and significance of novel tumour-testis antigens CT10, SSX1 induced by low dose of 5-aza-2’-deoxycytidine in hepatocellular carcinoma cell HepG2 |
| ZHANG He ZHAO Huixia ZENG Zhiyan LI Qingyan YUN Chao GUAN Na LI Quiwen XIAO Wenhua |
| Department of Oncology, Fourth Medical Center of People’s Liberation Army General Hospital, Beijing 100048, China |
|
|
|
Abstract Objective To explore expression and significance of novel tumour-testis antigens CT10, SSX1 induced by low dose of 5-aza-2’-deoxycytidine(5-aza-CdR) in hepatocellular carcinoma cell HepG2. Methods The six mRNA expression of MAGE1, MAGE3, CT10, CTp11, NE-ESO-1, and SSX1 in HepG2, SMMC-7721, BEL-7402, MHCC97L and MHCC97M3 liver cancer cell lines were detected by RT-PCR. HepG2 cells that do not express CT10 and SSX1 were selected as the study object as nCTAs, and HepG2 cells were treated with 0, 0.5, 1.0, and 1.5 μmol/L 5-aza-CdR. The control group did not contain 5-aza-CdR, from low to high concentration, they were experiment 1, 2, and 3 groups respectively, the mRNA and protein expressions of CT10 and SSX1 were detected by RT-PCR and Western blot, respectively. Results Different nCTAs expression was found in five hepatocellular cells, the expression was heterogeneous, among them MAGE1, MAGE3, CTp11, and NY-ESO-1 expression in HepG2; MAGE1, MAGE3, CT10, CTp11, and SSX1 expression in both MHCC97L and MHCC97M3; MAGE1, MAGE3, and CTp11 expression in BEL-7402; however, SMMC-7721 only expresses MAGE1 and MAGE3. Experimental 1, 2, and 3 groups could induce the expression of CTA-CT10 and SSX1, among them, 0.5 μmol/L small dose of experiment group 1 could also induce the expression of nCTAs, the relative expression of nCTAs induced in experiment 3 group was significantly higher than that in experiment 1 and 2 group, and the differences were statistically significant (P＜0.05). Conclusion Different hepatocellular carcinoma cells expressed different CTAs, and a small dose of 5-aza-CdR could induce the expression of nCTAs in hepatocellular carcinoma cell lines.
|
|
|
|
|
|
[1] Sangro B，Sarobe P，Hervás-Stubbs S，et al. Advances in immunotherapy for hepatocellular carcinoma [J]. Nat Rev Gastroenterol Hepatol，2021，18（8）：525-543.
[2] Ma W，Pham B，Li T. Cancer neoantigens as potential targets for immunotherapy [J]. Clin Exp Metastasis，2021，5：1-10.
[3] Yang P，Meng M，Zhou Q. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy [J]. Biochim Biophys Acta Rev Cancer，2021， 1876（1）：188558.
[4] Schietinger A，Philip M，Krisnawan V，et al. Tumor-specific T cells dysfuction is a dynamic antgens-driven differentiation program initiated early during tumourigenesis [J]. Immunity，2016，45（2）：389-401.
[5] Xiao WH，Sanren GW，Zhu JH，et al. Effect of 5-Aza-2’- deoxycytidine on immune-associated proteins in exosomes from hepatoma [J]. World J Gastroentero，2010，16（19）：2371-2377.
[6] Yamamoto TN，Kishton RJ，Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors [J]. Nat Med，2019，25（10）：1488-1499.
[7] Meng X，Sun X，Liu Z，et al. A novel era of cancer/testis antigen in cancer immunotherapy [J]. Int Immunopharmacol，2021，98：107889.
[8] Bagchi S，Yuan R，Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer：Clinical Impact and Mechanisms of Response and Resistance [J]. Annu Rev Pathol，2021，16：223-249.
[9] Jerby-Arnon L，Shah P，Cuoco MS，et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade [J]. Cell，2018，175（4）：984-997.
[10] 肖文华，刘丽华.5-脱氧杂氮胞苷抑制肝癌细胞DNA甲基转移酶转录[J].肿瘤防治研究，2001，29（4）：294-295.
[11] Li Z，Guo P，Guo PY，et al. 5-aza-2’-deoxycytidine （DAC） treatment induces the MAGE-A10 expression and improves the cytotoxicity of MAGE-A10-specific CTLs in lung cancer cells [J]. Trans Cancer Res，2020，9（2）：1235-1245.
[12] Bull C，Mayrhofer G，Fenech M. Exposure to hypomethylating 5-aza-2’-dexoycytidine （decitabine） causes rapid，severe DNA damage，telomere elongation and mistotic dysfuction in human WIL2-NS cells [J]. Mut Res Gene Toxicol Environ Mutagen，2021，868-869：503385.
[13] Tsai HC，Li H，Neste LV，et al. Transient low doses of DNA demethylating agents exert durable anti-tumor effects on hemaotlogical and epithlial tumor cells [J]. Cancer Cell，2012，21（3）：430-446.
[14] Hill B，Jagadeesh D，Pohlman B，et al. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies [J]. Semin Hematol，2021，58（1）：35-44.
[15] Chi P，Wang X. Reactivation of oncogenes involved in G1/S transcription and apoptosis pathway by low dose decitabine promotes HT29 human colon cancer cell growth in vitro [J]. Am J Transl Res，2020，12（12）：7938-7952.
[16] Ge YY，Zhang QM，Liu C，et al. Combined treatment with epigenetic agents enhances anti-tumor activity of T cell by upregulating the ACRBP expression in hepatocellur carcinoma [J]. Am J Trans Res，2021，13（7）：7591-7609.
[17] Klasic M，Kristic J，Korac P，et al. DNA hypomethylation upregulate expression of the MGAT3 gene in HepG2 cells and leads to changes in N-glycosylation of secreted glycoproteins [J]. Sci Rep，2016，6：24363.
[18] Wu Y，Zhang X，Liu Y，et al. Decreased expression of BNC1 and BNC2 is associated with genetic or epgenetic regulation in hepatocellular carcinoma [J]. Int J Mol Sci，2016，17（2）：153.
[19] Karpf AR，Lasek AW，Ririe TO，et al. Limited gene activating in tumour and normal epithelial cells treated with the DNA methylatransferase inhibitor 5-aza-2’-doxycytidine [J]. Mol Pharmacol，2004，65：18-27.
[20] Jansen YTL，Verset G，Schats K，et al. Phase I clinical trial of decitabine （5-aza-2’-deoxycytidine）administered by hepatic arterial infusion in patients with unsectable liver-predominant metastases [J]. ESMO Open，2019，4（2）：e000464.
[21] Zhu H，Yang B，Liu J，et al. A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes [J]. Ther Adv Hematol，2021，12：1-10.
[22] Li H，Wang L，Wu Y，et al. Very-low-dose decitabine is effective in treating intermediate or high-risk myelodysplastic syndrome [J]. Acta Hematol，2017，138（3）：168-174.
[23] Wyli B，Chee J，Forbes CA，et al. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens [J]. Oncoimmunology，2019，8（8）：1609874.
[24] Chen M，Nie J，Liu Y，et al. Phse Ⅰb/Ⅱ study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer [J]. Int J Cancer，2018，143（6）：1530- 1540.
[25] Liu Y，Wang C，Li X，et al. Improved clinical outcome in a radomized phase Ⅱ study of anti-PD-1 Camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma [J]. J Immunother Cancer，2021，9（4）：e002347. |
|
|
|
